Page last updated: 2024-09-05

solifenacin succinate and Day Blindness

solifenacin succinate has been researched along with Day Blindness in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hsiao, SM; Kuo, HC; Lin, HH	1
Sand, PK	1
Cardozo, L; Chapple, C; Haab, F; Ridder, AM	1

Reviews

1 review(s) available for solifenacin succinate and Day Blindness

Article	Year
Elevating our therapeutic expectations in overactive bladder. Journal of the American Academy of Nurse Practitioners, 2004, Volume: 16, Issue:10 Suppl Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia	2004

Article

Year

Elevating our therapeutic expectations in overactive bladder.

Journal of the American Academy of Nurse Practitioners, 2004, Volume: 16, Issue:10 Suppl

Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia

2004

Trials

1 trial(s) available for solifenacin succinate and Day Blindness

Article	Year
Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. European urology, 2005, Volume: 47, Issue:3 Topics: Constipation; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia	2005

Article

Year

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.

European urology, 2005, Volume: 47, Issue:3

Topics: Constipation; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia

2005

Other Studies

1 other study(ies) available for solifenacin succinate and Day Blindness

Article	Year
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year. Lower urinary tract symptoms, 2018, Volume: 10, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Severity of Illness Index; Solifenacin Succinate; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Vision Disorders; Xerostomia; Young Adult	2018

Article

Year

Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.

Lower urinary tract symptoms, 2018, Volume: 10, Issue:1

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Severity of Illness Index; Solifenacin Succinate; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Vision Disorders; Xerostomia; Young Adult

2018